156 related articles for article (PubMed ID: 21393628)
1. Development of a high-throughput cell-based reporter assay for screening of JAK3 inhibitors.
Yin CH; Bach EA; Baeg GH
J Biomol Screen; 2011 Apr; 16(4):443-9. PubMed ID: 21393628
[TBL] [Abstract][Full Text] [Related]
2. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.
Kim BH; Jee JG; Yin CH; Sandoval C; Jayabose S; Kitamura D; Bach EA; Baeg GH
Mol Cancer; 2010 Feb; 9():36. PubMed ID: 20149240
[TBL] [Abstract][Full Text] [Related]
3. A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
Oh K; Joo KM; Jung YS; Lee J; Kang H; Lee HY; Lee DS
J Immunol Methods; 2010 Mar; 354(1-2):45-52. PubMed ID: 20138049
[TBL] [Abstract][Full Text] [Related]
4. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation.
Ross JA; Cheng H; Nagy ZS; Frost JA; Kirken RA
J Biol Chem; 2010 Feb; 285(6):3582-3591. PubMed ID: 19923221
[TBL] [Abstract][Full Text] [Related]
5. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
Ju W; Zhang M; Jiang JK; Thomas CJ; Oh U; Bryant BR; Chen J; Sato N; Tagaya Y; Morris JC; Janik JE; Jacobson S; Waldmann TA
Blood; 2011 Feb; 117(6):1938-46. PubMed ID: 21106989
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.
Kim BH; Kim M; Yin CH; Jee JG; Sandoval C; Lee H; Bach EA; Hahm DH; Baeg GH
Br J Pharmacol; 2011 Sep; 164(1):106-18. PubMed ID: 21434883
[TBL] [Abstract][Full Text] [Related]
7. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
8. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3.
Cortes JR; Perez-G M; Rivas MD; Zamorano J
J Immunol; 2007 Sep; 179(6):3881-7. PubMed ID: 17785825
[TBL] [Abstract][Full Text] [Related]
9. Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
Yu V; Pistillo J; Archibeque I; Han Lee J; Sun BC; Schenkel LB; Geuns-Meyer S; Liu L; Emkey R
Exp Hematol; 2013 May; 41(5):491-500. PubMed ID: 23340136
[TBL] [Abstract][Full Text] [Related]
10. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex.
Rodriguez G; Ross JA; Nagy ZS; Kirken RA
J Biol Chem; 2013 Mar; 288(10):7137-46. PubMed ID: 23341462
[TBL] [Abstract][Full Text] [Related]
11. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity.
Kim BH; Oh SR; Yin CH; Lee S; Kim EA; Kim MS; Sandoval C; Jayabose S; Bach EA; Lee HK; Baeg GH
Br J Haematol; 2010 Jan; 148(1):132-43. PubMed ID: 19793252
[TBL] [Abstract][Full Text] [Related]
12. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
13. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.
Chang BY; Zhao F; He X; Ren H; Braselmann S; Taylor V; Wicks J; Payan DG; Grossbard EB; Pine PR; Bullard DC
J Immunol; 2009 Aug; 183(3):2183-92. PubMed ID: 19596999
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
15. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
16. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
17. [The STAT5 signaling in the expression of alpha-subunit of interleukin-2 receptor in human blood lymphocytes].
Mitiushova EV; Shatrova AN; Zenin VV; Aksenov ND; Marakhova II
Tsitologiia; 2013; 55(6):421-9. PubMed ID: 25509109
[TBL] [Abstract][Full Text] [Related]
18. Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta.
Zhu MH; Berry JA; Russell SM; Leonard WJ
J Biol Chem; 1998 Apr; 273(17):10719-25. PubMed ID: 9553136
[TBL] [Abstract][Full Text] [Related]
19. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
